Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tyra Biosciences SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company developing FGFR-focused precision medicines. Recent 8-K reports cover operating results, clinical-program updates for TYRA-300/dabogratinib, officer and board appointments, and capital actions under a registered at-the-market offering program.
Proxy materials describe annual meeting voting matters, board structure and corporate-governance procedures. Registration-linked disclosures and material-event reports also identify TYRA common stock, equity issuance activity, and the company’s use of SEC exhibits for press releases and other official corporate records.
Tyra Biosciences, Inc. amendment to a Schedule 13G/A reports that Commodore Capital entities and two managing partners beneficially own 2,475,000 shares of Common Stock as of March 31, 2026. The filing states this equals 4.2% of the class using 59,469,687 shares outstanding as of March 31, 2026.
The report attributes the position to Commodore Capital LP and Commodore Capital Master LP, with Michael Kramarz and Robert Egen Atkinson identified as managing partners exercising investment discretion. The filing is signed and dated May 15, 2026.
Tyra Biosciences, Inc. holdings disclosed by Janus Henderson Group plc via an amended Schedule 13G/A reporting 3,890,589 common shares, representing 7.2% of the class. The filing states the Asset Managers exercise shared voting and dispositive power over these shares.
The disclosure clarifies the Asset Managers act on behalf of Managed Portfolios and disclaim rights to receive dividends or sale proceeds; signature dated 5/15/2026.
Tyra Biosciences reports a Schedule 13G/A showing beneficial ownership by Todd Harris. As of March 31, 2026, the company reported 59,469,687 shares outstanding. The Reporting Person beneficially owns 2,913,342 shares, or 4.8% of the class, consisting of 1,358,631 shares held directly and 1,554,711 shares underlying options exercisable within 60 days.
The filing confirms sole voting and dispositive power over all 2,913,342 shares.
Tyra Biosciences reported a larger net loss for the quarter ended March 31, 2026 as it increased investment in its pipeline. Net loss was $39.3 million, compared with $28.1 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $33.5 million, while general and administrative costs were $8.5 million. The company strengthened its balance sheet by raising $147.9 million via an at-the-market stock program, ending the quarter with $383.5 million in cash, cash equivalents and marketable securities and stating this should fund operations into the second half of 2028.
Tyra Biosciences reported a first quarter 2026 net loss of $39.3 million, wider than $28.1 million a year earlier, as it increased spending to advance its pipeline. Research and development expenses rose to $33.5 million, driven by Phase 2 trials for oral dabogratinib in urologic cancers and achondroplasia and start-up costs for the SURF303 study.
General and administrative expenses were $8.5 million compared with $6.9 million in 2025, reflecting higher personnel costs. Tyra ended March 31, 2026 with cash, cash equivalents and marketable securities of $383.5 million, which it expects will fund operations into the second half of 2028. The company also issued shares under its at-the-market program and continues to progress multiple Phase 2 studies under its “dabogratinib 3x3” strategy.
TYRA reported Form 144 sale notices by an affiliate (Daniel Bensen) describing dispositions of Common stock. The excerpt lists three transactions of 8,000 shares each on 02/12/2026, 03/12/2026, and 04/13/2026 with reported dollar amounts of $262,000, $181,000, and $285,000 respectively. The filing also shows a line with 53,372,098 and the date 05/12/2026, presented in the excerpt alongside exchange Nasdaq.
Tyra Biosciences, Inc. ownership disclosure: an Amendment No. 1 to a Schedule 13G/A filed by Farallon-related entities updates shared beneficial ownership figures for Common Stock (CUSIP 90240B106). The filing lists multiple Farallon funds and affiliated persons holding between 74,008 and 3,580,818 shares per line, with several entries showing single-filer holdings of 3,580,818 (representing 6.6%) and 3,407,712 (representing 6.3%).
The filing states the Farallon Funds hold the reported Shares directly and describes the fund/GP/individual relationships and disclaimers of beneficial ownership by certain entities and individuals. The Schedule is filed pursuant to Section 240.13d-1(c) and identifies the Reporting Persons and their principal business office.
Tyra Biosciences, Inc. reported that Chief Medical Officer Douglas J. Warner received new equity awards as part of his compensation. He was granted 25,000 restricted stock units (RSUs), each representing one share of common stock, with one quarter vesting on each of the first four anniversaries of May 5, 2026, subject to his continuous service. He also received a stock option for 85,000 shares of common stock at an exercise price of $33.93 per share, vesting in equal monthly installments over 48 months following May 5, 2026, also conditioned on continued service. These are grants and not open‑market purchases or sales.
Tyra Biosciences, Inc. granted Chief Financial Officer Alan Fuhrman new equity awards on May 5, 2026. He received 20,000 restricted stock units, which vest in four equal annual installments starting on May 5, 2027, each RSU representing one share of common stock. He was also granted options on 67,000 shares of common stock at an exercise price of $33.93 per share, vesting monthly over four years and expiring on May 4, 2036. Following these awards, he directly owns 36,164 shares of common stock, including RSUs.
Tyra Biosciences President and CEO Harris Todd received new equity awards that increase his long-term stake in the company. He was granted 79,000 restricted stock units on May 5, 2026, bringing his direct common stock holdings to 1,437,631 shares after the award.
He also received a stock option for 265,000 shares of common stock at an exercise price of $33.93 per share, expiring on May 4, 2036. The RSUs vest in four equal annual installments starting on the first anniversary of May 5, 2026, while the option vests monthly over 48 months from the same date, in each case subject to his continuous service.